Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Substrate Selectivity Check of the Ergothioneine Transporter.

Tschirka J, Kreisor M, Betz J, Gründemann D.

Drug Metab Dispos. 2018 Jun;46(6):779-785. doi: 10.1124/dmd.118.080440. Epub 2018 Mar 12.

PMID:
29530864
2.

Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.

Vollmar J, Lautem A, Closs E, Schuppan D, Kim YO, Grimm D, Marquardt JU, Fuchs P, Straub BK, Schad A, Gründemann D, Schattenberg JM, Gehrke N, Wörns MA, Baumgart J, Galle PR, Zimmermann T.

Oncotarget. 2017 Dec 18;8(70):115667-115680. doi: 10.18632/oncotarget.23372. eCollection 2017 Dec 29.

3.

Ergothioneine stands out from hercynine in the reaction with singlet oxygen: Resistance to glutathione and TRIS in the generation of specific products indicates high reactivity.

Stoffels C, Oumari M, Perrou A, Termath A, Schlundt W, Schmalz HG, Schäfer M, Wewer V, Metzger S, Schömig E, Gründemann D.

Free Radic Biol Med. 2017 Dec;113:385-394. doi: 10.1016/j.freeradbiomed.2017.10.372. Epub 2017 Oct 23.

PMID:
29074402
4.

Ergothioneine and related histidine derivatives in the gas phase: tautomer structures determined by IRMPD spectroscopy and theory.

Peckelsen K, Martens J, Czympiel L, Oomens J, Berden G, Gründemann D, Meijer AJHM, Schäfer M.

Phys Chem Chem Phys. 2017 Aug 30;19(34):23362-23372. doi: 10.1039/c7cp03843g.

PMID:
28825745
5.

Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state.

Schommers P, Thurau A, Bultmann-Mellin I, Guschlbauer M, Klatt AR, Rozman J, Klingenspor M, de Angelis MH, Alber J, Gründemann D, Sterner-Kock A, Wiesner RJ.

Mol Metab. 2017 May 5;6(7):737-747. doi: 10.1016/j.molmet.2017.05.002. eCollection 2017 Jul.

6.

A novel mode of operation of SLC22A11: Membrane insertion of estrone sulfate versus translocation of uric acid and glutamate.

Skwara P, Schömig E, Gründemann D.

Biochem Pharmacol. 2017 Mar 15;128:74-82. doi: 10.1016/j.bcp.2016.12.020. Epub 2016 Dec 25.

PMID:
28027879
7.

Knockout of the ergothioneine transporter ETT in zebrafish results in increased 8-oxoguanine levels.

Pfeiffer C, Bach M, Bauer T, Campos da Ponte J, Schömig E, Gründemann D.

Free Radic Biol Med. 2015 Jun;83:178-85. doi: 10.1016/j.freeradbiomed.2015.02.026. Epub 2015 Mar 5.

PMID:
25746775
8.

Inhibition of human organic cation transporters by the alkaloids matrine and oxymatrine.

Pan X, Wang L, Gründemann D, Sweet DH.

Fitoterapia. 2014 Jan;92:206-10. doi: 10.1016/j.fitote.2013.11.009. Epub 2013 Nov 27.

PMID:
24291757
9.

SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct.

Schulz C, Fork C, Bauer T, Golz S, Geerts A, Schömig E, Gründemann D.

Biochem J. 2014 Jan 15;457(2):243-51. doi: 10.1042/BJ20130654.

PMID:
24147638
10.

Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.

Pan X, Wang L, Gründemann D, Sweet DH.

Antimicrob Agents Chemother. 2013 Oct;57(10):5053-9. doi: 10.1128/AAC.01255-13. Epub 2013 Aug 5.

11.

Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Mulgaonkar A, Venitz J, Gründemann D, Sweet DH.

Antimicrob Agents Chemother. 2013 Jun;57(6):2705-11. doi: 10.1128/AAC.02289-12. Epub 2013 Apr 1.

12.

Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2.

Pfennig T, Herrmann B, Bauer T, Schömig E, Gründemann D.

Biochim Biophys Acta. 2013 Feb;1828(2):491-8. doi: 10.1016/j.bbamem.2012.08.026. Epub 2012 Sep 7.

13.

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.

Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, Foltys D, Weiler N, Zimmermann A, Schad A, Gründemann D, Otto G, Galle PR, Schuchmann M, Zimmermann T.

BMC Cancer. 2012 Mar 22;12:109. doi: 10.1186/1471-2407-12-109.

14.

Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action.

Zhu HJ, Appel DI, Gründemann D, Richelson E, Markowitz JS.

Pharmacol Res. 2012 Apr;65(4):491-6. doi: 10.1016/j.phrs.2012.01.008. Epub 2012 Feb 8.

PMID:
22342816
15.

The ergothioneine transporter controls and indicates ergothioneine activity--a review.

Gründemann D.

Prev Med. 2012 May;54 Suppl:S71-4. doi: 10.1016/j.ypmed.2011.12.001. Epub 2011 Dec 13. Review.

PMID:
22182480
16.

Paramount levels of ergothioneine transporter SLC22A4 mRNA in boar seminal vesicles and cross-species analysis of ergothioneine and glutathione in seminal plasma.

Nikodemus D, Lazic D, Bach M, Bauer T, Pfeiffer C, Wiltzer L, Lain E, Schömig E, Gründemann D.

J Physiol Pharmacol. 2011 Aug;62(4):411-9.

17.

OAT2 catalyses efflux of glutamate and uptake of orotic acid.

Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D, Schömig E, Gründemann D.

Biochem J. 2011 Jun 1;436(2):305-12. doi: 10.1042/BJ20101904.

PMID:
21446918
18.

Interaction of organic cation transporter 3 (SLC22A3) and amphetamine.

Zhu HJ, Appel DI, Gründemann D, Markowitz JS.

J Neurochem. 2010 Jul;114(1):142-9. doi: 10.1111/j.1471-4159.2010.06738.x. Epub 2010 Apr 6.

19.

Substrate discrimination by ergothioneine transporter SLC22A4 and carnitine transporter SLC22A5: gain-of-function by interchange of selected amino acids.

Bacher P, Giersiefer S, Bach M, Fork C, Schömig E, Gründemann D.

Biochim Biophys Acta. 2009 Dec;1788(12):2594-602. doi: 10.1016/j.bbamem.2009.09.019. Epub 2009 Oct 6.

20.

Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.

Bayer M, Kuçi Z, Schömig E, Gründemann D, Dittmann H, Handgretinger R, Bruchelt G.

Nucl Med Biol. 2009 Apr;36(3):287-94. doi: 10.1016/j.nucmedbio.2008.12.010.

PMID:
19324274
21.

Decreased anxiety in mice lacking the organic cation transporter 3.

Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AF, Gründemann D, Schömig E, Lesch KP, Gerlach M, Reif A.

J Neural Transm (Vienna). 2009 Jun;116(6):689-97. doi: 10.1007/s00702-009-0205-1. Epub 2009 Mar 11.

PMID:
19280114
22.

The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate.

Grigat S, Fork C, Bach M, Golz S, Geerts A, Schömig E, Gründemann D.

Drug Metab Dispos. 2009 Feb;37(2):330-7. doi: 10.1124/dmd.108.023929. Epub 2008 Nov 3.

23.

Simultaneous fitting of real-time PCR data with efficiency of amplification modeled as Gaussian function of target fluorescence.

Batsch A, Noetel A, Fork C, Urban A, Lazic D, Lucas T, Pietsch J, Lazar A, Schömig E, Gründemann D.

BMC Bioinformatics. 2008 Feb 12;9:95. doi: 10.1186/1471-2105-9-95.

24.

Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.

Lazar A, Gründemann D, Schömig E.

Mol Diagn Ther. 2007;11(5):341; author reply 341-2. No abstract available.

PMID:
17963423
25.

Probing the substrate specificity of the ergothioneine transporter with methimazole, hercynine, and organic cations.

Grigat S, Harlfinger S, Pal S, Striebinger R, Golz S, Geerts A, Lazar A, Schömig E, Gründemann D.

Biochem Pharmacol. 2007 Jul 15;74(2):309-16. Epub 2007 Apr 22.

PMID:
17532304
26.

Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder.

Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B, Gründemann D, Grimberg G, Schulz E, Remschmidt H, Wewetzer C, Schömig E.

Int J Neuropsychopharmacol. 2008 Feb;11(1):35-48. Epub 2007 May 4.

PMID:
17477885
27.

Mechanism of Ca(v)1.2 channel modulation by the amino terminus of cardiac beta2-subunits.

Herzig S, Khan IF, Gründemann D, Matthes J, Ludwig A, Michels G, Hoppe UC, Chaudhuri D, Schwartz A, Yue DT, Hullin R.

FASEB J. 2007 May;21(7):1527-38. Epub 2007 Feb 8.

PMID:
17289923
28.

Fast set-up of doxycycline-inducible protein expression in human cell lines with a single plasmid based on Epstein-Barr virus replication and the simple tetracycline repressor.

Bach M, Grigat S, Pawlik B, Fork C, Utermöhlen O, Pal S, Banczyk D, Lazar A, Schömig E, Gründemann D.

FEBS J. 2007 Feb;274(3):783-90.

29.

Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension.

Lazar A, Zimmermann T, Koch W, Gründemann D, Schömig A, Kastrati A, Schömig E.

Clin Exp Hypertens. 2006 Oct;28(7):645-53.

PMID:
17060063
30.

Contribution of allelic variations in transporters to the phenotype of drug response.

Kirchheiner J, Gründemann D, Schömig E.

J Psychopharmacol. 2006 Jul;20(4 Suppl):27-32. Review.

PMID:
16785267
31.

Extraneuronal monoamine transporter and organic cation transporters 1 and 2: a review of transport efficiency.

Schömig E, Lazar A, Gründemann D.

Handb Exp Pharmacol. 2006;(175):151-80. Review.

PMID:
16722235
32.

Are organic cation transporters capable of transporting prostaglandins?

Harlfinger S, Fork C, Lazar A, Schömig E, Gründemann D.

Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30. Epub 2005 Oct 7.

PMID:
16211406
33.

Discovery of the ergothioneine transporter.

Gründemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schömig E.

Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5256-61. Epub 2005 Mar 28.

34.

Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action.

Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E.

Br J Pharmacol. 2004 Sep;143(1):159-65. Epub 2004 Aug 2.

35.

Agmatine signaling: odds and threads.

Berkels R, Taubert D, Gründemann D, Schömig E.

Cardiovasc Drug Rev. 2004 Spring;22(1):7-16. Review.

PMID:
14978515
36.

The localisation of the extraneuronal monoamine transporter (EMT) in rat brain.

Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E.

J Neurochem. 2004 Jan;88(2):291-7.

37.

PCR-generated truncated positive control for PCR screening of embryonic stem cell clones.

Gründemann D, Censarek P, Schömig E.

Biotechniques. 2003 Jun;34(6):1130-2, 1134. No abstract available.

PMID:
12813876
38.

Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).

Lazar A, Gründemann D, Berkels R, Taubert D, Zimmermann T, Schömig E.

J Hum Genet. 2003;48(5):226-30. Epub 2003 Apr 9.

PMID:
12768439
39.

Detection of a novel 1905C-->T mutation within the dihydropyrimidine dehydrogenase gene and potential for misclassification with the exon 14-skipping mutation.

Lazar A, Jan Weissenborn S, Gründemann D, Berkels R, Fuhr U, Pfister H, Schömig E.

Clin Chem. 2003 Apr;49(4):707-8. No abstract available.

40.
41.

Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells.

Gründemann D, Koschker AC, Haag C, Honold C, Zimmermann T, Schömig E.

Br J Pharmacol. 2002 Nov;137(6):910-8.

42.

A simple method for elimination of false positive results in RT-PCR.

Martel F, Gründemann D, Schömig E.

J Biochem Mol Biol. 2002 Mar 31;35(2):248-50.

PMID:
12297038
43.

Binding of [(3)H]prazosin to alpha(1A)- and alpha(1B)-adrenoceptors, and to a cimetidine-sensitive non-alpha(1) binding site in rat kidney membranes.

Mugisha P, Gründemann D, Schömig E, Uhlén S.

Naunyn Schmiedebergs Arch Pharmacol. 2002 May;365(5):335-40. Epub 2002 Apr 5.

PMID:
12012018
44.

Regulation of human extraneuronal monoamine transporter (hEMT) expressed in HEK293 cells by intracellular second messenger systems.

Martel F, Keating E, Calhau C, Gründemann D, Schömig E, Azevedo I.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):487-95.

PMID:
11770002
45.

Apical uptake of organic cations by human intestinal Caco-2 cells: putative involvement of ASF transporters.

Martel F, Gründemann D, Calhau C, Schömig E.

Naunyn Schmiedebergs Arch Pharmacol. 2001 Jan;363(1):40-9.

PMID:
11191835
46.

Gene structures of the human non-neuronal monoamine transporters EMT and OCT2.

Gründemann D, Schömig E.

Hum Genet. 2000 Jun;106(6):627-35.

PMID:
10942111
47.

Selective substrates for non-neuronal monoamine transporters.

Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E.

Mol Pharmacol. 1999 Jul;56(1):1-10.

48.

Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.

Gründemann D, Schechinger B, Rappold GA, Schömig E.

Nat Neurosci. 1998 Sep;1(5):349-51. No abstract available.

PMID:
10196521
49.

Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.

Gründemann D, Köster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermüller N, Schömig E.

J Biol Chem. 1998 Nov 20;273(47):30915-20.

50.

Catecholamine transport by the organic cation transporter type 1 (OCT1).

Breidert T, Spitzenberger F, Gründemann D, Schömig E.

Br J Pharmacol. 1998 Sep;125(1):218-24.

Supplemental Content

Loading ...
Support Center